Navigation Links
Phosphagenics' A$19.3 million Capital Raising
Date:7/11/2014

MELBOURNE, Australia, July 11, 2014 /PRNewswire/ -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$19.3 million via a placement of A$16.3 million to institutional investors in Europe, the U.S., Asia and Australia and A$3 million from a share purchase plan (SPP) to be offered to existing shareholders.  The placement of A$16.3 million will be made in two tranches.

"This capital raising positions us strongly to fulfil our commercialisation objectives and fully funds our scheduled TPM®/opioid clinical trial programs.  The capital raised is earmarked for our pivotal TPM®/Oxymorphone Phase 2 clinical trial in the USA scheduled for the first half of 2015 and our upcoming TPM®/Oxycodone Phase 2 trial in Australia," said CEO, Harry Rosen.

"The capital raising comes at a time when the Company is focusing on exploiting the commercialization of several of its lead programs.  We have recently strengthened our business development capacity in the U.S. to assist in this process.  While we have unquestionably shown that our technology provides enhanced delivery solutions across a wide range of products, we now need to translate this to commercial outcomes," said Harry Rosen.

The completion of this capital raising and the investment by new and existing institutional shareholders is a strong endorsement of the TPM® technology and commercial prospects of Phosphagenics.

The institutional placement is for initially 153,000,000 shares at 8 cents per share. This represents a discount of 11% to the last sale price of 9 cents.  A placement of a further 51,000,000 shares at the same pric
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phosphagenics Appoints Neura Therapeutik as US Strategic Commercial Advisors
2. Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million
3. University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services
4. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
5. 2013 Was a Multimillion-Dollar Year for The Trendlines Group
6. Isis Pharmaceuticals to Receive $7.5 Million from Alnylam
7. Sanomedics Secures $5 Million Revolving Credit Facility With TCA Global Credit Master Fund, LP To Fund Growth And Future Acquisitions
8. Forus Health Raises Rs 50 Crore ($8.2 Million) in Series B Funding Led by Asian Healthcare Fund
9. Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
10. Oxford Finance Closes $25 Million Senior Credit Facility with Entellus Medical
11. Auspex Raises $35 Million And Appoints Industry Veteran Gerald Proehl To Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... MYL ) shareholder vote regarding its planned unsolicited offer ... offer to Perrigo shareholders have always been, and will ... of the value available to Perrigo shareholders, and do ... allowed its shareholders to consider," said Joseph C. ...
(Date:8/28/2015)... 2015 The report "Eubiotics Market by Type (Probiotics, ... and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends and ... Eubiotics was valued at USD 4.62 Billion in 2014 and ... a CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Merrimack Pharmaceuticals, Inc. announced today that the first ... study combining MM-121, a fully human monoclonal antibody that ... for patients with advanced solid tumors. ... evaluates the safety and pharmacokinetics of MM-121 when administered ...
... LLC has hired nutritional brand marketing expert Tom Hall ... will apply his 30 years of executive marketing experience ... to launch new company products in the international marketplace. ... "Tom,s extensive experience and success in product ...
Cached Medicine Technology:Tom Hall Named National Sales and Marketing Director for VR Laboratories 2Tom Hall Named National Sales and Marketing Director for VR Laboratories 3
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris ... college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio ... expand its reach and impact through innovative technologies and strategies. , “I am very ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , ... 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... until it encounters a cancer cell, then suddenly activates and ... marks the latest step in scientists, efforts to tap the ... of the technology at the University of Rochester Medical Center ... machines produced in abundance by tumors to chew through and ...
... a major public health problem through its association with ... life expectancy rises around the world, along with the ... incidence of hip fractures is estimated to reach 6.3 ... of fracture in men and women. A new review ...
... on the words ,light, and ,mild, smokers in Western ... may be less harmful than others. In fact, ... of risk to smokers, including ,mild, and ,low-tar, brands. ... Addiction polled over 8000 smokers from Australia, Canada, ...
... Amanda Gardner HealthDay Reporter , MONDAY, April 11 ... primary care doctors often choose a different option than they ... In fact, physicians who were surveyed in the research more ... to have long-term repercussions, such as paralysis, than to die. ...
... University researcher has co-authored an international study that revealed a ... treat a rare lung disease in women. The life-threatening ... The clinical trial of the drug -- called sirolimus ... a therapy for the lung disease, lymphangioleiomyomatosis, or LAM. ...
... -- Long-term use of antibiotics to treat acne doesn,t ... medications, a new study finds. The finding came ... of antibiotics has been credited with encouraging antibiotic resistance ... Pennsylvania School of Medicine assessed the prevalence of ...
Cached Medicine News:Health News:A 'Pacman strategy' to boost the immune system to fight cancer 2Health News:A 'Pacman strategy' to boost the immune system to fight cancer 3Health News:Changing trends in hip fracture incidence around the world 2Health News:Smokers believe 'silver', 'gold' and 'slim' cigarettes are less harmful 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 3Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Acne Antibiotics Not Linked to Drug Resistance 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... a monopolar cautery connector extending from the ... used for electrosurgery when properly attached to ... ,Ethicon Endo-Surgery provides disposable handheld instruments ... Our handheld instruments come in 5mm and ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: